Macrophages, granulocytes, many lymphocytes, and certain epithelia all express receptors for the Fc domain of IgG. Fc receptors (FcR) serve diverse functions in cellular and humoral immunity. In macrophages, they mediate the endocytosis soluble antibody-antigen complexes, the phagocytosis of large IgG-coated particles, and the release of potent cytotoxic and inflammatory agents. FcR on B-lymphocytes, on the other hand, regulate the process of B-cell activation via surface Ig. Recently, this diversity in function has been found to reflect an even greater diversity in structure. FcR comprise a large, multi-gene family of Ig-related molecules. Among the most important of these if FcRII, a receptor class expressed on virtually all FcR-positive cells. However, even this single class exhibits considerable structural heterogeneity due to cell type-specific alternative mRNA splicing that generates receptors with different cytoplasmic domains. In murine cells, the major splice products are mFcRII-B1 (lymphocytes) and -B2 (macrophages). These isoforms are identical except for an in-frame insertion of 47 amino acids in the cytoplasmic tail of mFcRII-B1. Over the past few years, we have begun to establish the functional differences between mFcRII-B1 and -B2, and to determine whether different receptor activities are associated with distinct regions of the FcRII cytoplasmic domain. For example, the presence of the insertion completely blocks endocytosis by preventing receptor accumulation at coated pits. In this proposal, we will extend these investigations using a combination of biochemical, molecular, morphological, and genetic approaches. First, we will better define the unique features of the FcRII-B2 coated pit localization domain. Although coated pit accumulation involves a conserved tyrosine-containing region of the receptor's cytoplasmic tail, more detailed analysis is required since unlike most other plasma membrane receptors the tyrosine residue itself is not required for coated pit localization in all cell types. Using molecular and biophysical approaches, the FcRII coated pit domain will be precisely defined and compared to more """"""""conventional"""""""" coated pit domains. Second, we will define the mechanism by which the alternatively spliced insertion in mFcRII-B1 (and its human homolog) prevents coated pit localization. Preliminary evidence suggests that the insertion functions by actively preventing coated pit entry, perhaps by binding the receptor to the cytoskeleton. Third, we will define the domains involved in the regulation of B-cell activation. The role of tyrosine phosphorylation will be evaluated since this domain appears to overlap with the region required for coated pit localization, and its tyrosine falls within a consensus tyrosine phosphorylation site. Fourth, we will identify sequences required for FcRII-mediated phagocytosis and signal transduction in transfected fibroblasts and macrophage lines. Finally, we will develop the use of a genetically manipulable professional phagocyte, Dictyostelium discoideum, as a genetic system for the study of phagocytosis in general and FcRII function in particular.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI034098-02
Application #
2069187
Study Section
Immunobiology Study Section (IMB)
Project Start
1993-03-01
Project End
1996-02-28
Budget Start
1994-03-01
Budget End
1995-02-28
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Yale University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Di Pucchio, Tiziana; Chatterjee, Bithi; Smed-Sorensen, Anna et al. (2008) Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 9:551-7
Yan, Jun; Wolff, Martin J; Unternaehrer, Julia et al. (2005) Targeting antigen to CD19 on B cells efficiently activates T cells. Int Immunol 17:869-77
Holcombe, Hilda; Mellman, Ira; Janeway Jr, Charles A et al. (2002) The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation. J Immunol 169:4982-9
Pierre, P; Shachar, I; Matza, D et al. (2000) Invariant chain controls H2-M proteolysis in mouse splenocytes and dendritic cells. J Exp Med 191:1057-62
Turley, S J; Inaba, K; Garrett, W S et al. (2000) Transport of peptide-MHC class II complexes in developing dendritic cells. Science 288:522-7
Inaba, K; Turley, S; Iyoda, T et al. (2000) The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 191:927-36
Garrett, W S; Chen, L M; Kroschewski, R et al. (2000) Developmental control of endocytosis in dendritic cells by Cdc42. Cell 102:325-34
Inaba, K; Turley, S; Yamaide, F et al. (1998) Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188:2163-73
Pierre, P; Mellman, I (1998) Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 93:1135-45